Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sang-Mi Kim has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Essential Data Elements for Laboratory Test Interoperability: An Expert Consensus-Based Framework

    by Ha Nui Kim, Min-Sun Kim, Sollip Kim, Kuenyoul Park, Eun-Jung Cho, Hyejin Ryu, YeJin Oh, Shinae Yu, John Hoon Rim, Sang-Mi Kim, et al.

    Ha Nui Kim, M.D., Min-Sun Kim, M.D., Sollip Kim, M.D., Kuenyoul Park, M.D., Eun-Jung Cho, M.D., Hyejin Ryu, M.D., YeJin Oh, M.D., Shinae Yu, M.D., John Hoon Rim, M.D., Sang-Mi Kim, M.D., Geon Park, M.D., Jaehyeon Lee, M.D., Hyun-Seung Lee, M.D., Hyun-Woo Choi, M.D., You Kyoung Lee, M.D., Jeong Hwan Shin, M.D., Sang-Guk Lee, M.D., Young Kyung Lee, M.D., Jeong-Yeal Ahn, M.D., Sail Chun, M.D., Jungchan Park, M.D., Jong-Yeup Kim, M.D., Hye Hyeon Kim, Ph.D., AeKyung Kwon, M.S., Kyunghoon Lee, M.D., Yeo-Min Yun, M.D., Dongheui An, M.D., Soyoun Shin, M.D., HyunYoung Ji, M.D., On behalf of the Standardization Management Committee of the Laboratory Medicine Foundation, and On behalf of the Clinical Practice Guidelines Committee of the Korean Society for Laboratory Medicine. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2026.0051


  • Open Access

    Targeted Comprehensive Screening of Neuropsychiatric Drugs in Serum by LC-MS/MS: Method Development and Three-Year Clinical Utility

    by Eunbin Chong, Se-Eun Koo, Sang-Mi Kim, Miryung Chun, Eun Yeon Joo, Hong Jin Jeon, Soo-Youn Lee

    The increasing prevalence of neuropsychiatric medication misuse highlights the critical need for efficient drug screening in clinical laboratories. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) application for broad serum drug screening remains limited in many clinical settings. Serum analysis is particularly valuable for identifying current drug exposure, confirming the cause of intoxication, and monitoring patient medication adherence. This study aimed to develop and validate an LC-MS/MS method using multiple reaction monitoring followed by information-dependent acquisition-triggered enhanced product ion scans for the simultaneous qualitative identification of 77 neuropsychiatric drugs, and to present its large-scale clinical application over three years. Validation included precision, accuracy, recovery, matrix effects, selectivity, and interference. A minimal serum volume (20 μL) underwent simple protein precipitation, with preparation time under 15 minutes per batch. This method was applied to 1,021 clinical serum specimens. Chromatographic separation was completed in 15 minutes. The precisions (CV) for calculated concentrations and retention times were < 30% and < 1.5%, respectively. Accuracy was assessed for 60 of the 77 analytes (100% agreement). Mean recovery and matrix effects were 93.1% and 99.9%, respectively. Most test orders originated from psychiatry and neurology outpatients. Although fewer orders came from the Department of Emergency Medicine (EM), the EM patients exhibited a higher positivity rate. The most frequently detected drug classes were benzodiazepines (37.9%), antidepressants (30.7%), and antipsychotics (19.7%). Common specific analytes included clonazepam/7-aminoclonazepam (10.2%) and lorazepam (10.0%). We developed and validated a LC-MS/MS method for the simultaneous detection of a wide range of neuropsychiatric drugs. The method proved essential for verifying medication history, identifying non-adherence, and diagnosing acute intoxication. Our findings highlight the critical role of broad-spectrum serum screening in managing medication-related emergencies and optimizing long-term therapeutic care.

  • Resolving falsely elevated vancomycin levels in KIMS immunoassay due to monoclonal IgM interference

    by Go Eun Bae, Sang-Mi Kim, Hae-Il Park, Soo-Youn Lee, Hyung-Doo Park

    Given its narrow therapeutic index and risk of nephrotoxicity, vancomycin requires accurate concentration monitoring. While immunoassays such as the Kinetic Interaction of Microparticles in Solution (KIMS) are widely used for their speed and simplicity, they are susceptible to interference by paraproteins such as monoclonal immunoglobulins. Here, we present the first case of falsely elevated vancomycin concentrations measured by KIMS due to monoclonal IgM interference, indicated by a 'kinetic flag' error, and evaluated pre-analytical approaches to mitigate this interference. We applied three pre-analytical techniques to overcome this issue: dithiothreitol (DTT) treatment to reduce disulfide bonds in IgM, ultrafiltration with a 100-kDa cutoff to physically remove IgM molecules, and heterophilic blocking tubes (HBT) to neutralize nonspecific binding by heterophilic antibodies. Vancomycin concentrations were measured using both KIMS (Cobas c702, Roche Diagnostics) and Chemiluminescent Microparticle Immunoassay (CMIA, Architect i2000SR, Abbott Laboratories). In pre-vancomycin-dose samples, both DTT treatment and ultrafiltration resolved the 'kinetic flag' error and corrected vancomycin concentrations to below the lower limit of quantification (LLOQ). In post-vancomycin-dose samples, DTT reduced vancomycin concentration to 16.82 μg/mL (93.8% of the naïve concentration), while ultrafiltration reduced it to 9.22 μg/mL (51.4%). HBT treatment did not resolve the error, and falsely elevated results persisted. This study reports the first case of IgM paraprotein interfering with vancomycin measurement by KIMS, underlining the importance of recognizing monoclonal IgM as a potential source of interference. DTT treatment effectively corrected the interference, while ultrafiltration reduced vancomycin concentration, highlighting the need for careful interpretation.

  • Open Access

    Carrier Frequency and Prevalence of Citrin Deficiency in East Asians and Koreans Based on Comprehensive Analysis of Pathogenic SLC25A13 Variants

    by Mi-Ae Jang, Won Young Heo, Jong Kwon Lee, Jong-Won Kim, Sang-Mi Kim, Ja-Hyun Jang, Hyung-Doo Park

    Citrin deficiency is an autosomal recessive disorder caused by pathogenic variants in SLC25A13, presenting with various age-dependent clinical phenotypes and a broad spectrum of severity. However, few studies have examined the frequency and prevalence of citrin deficiency. We aimed to analyze the carrier frequency and disease prevalence in East Asian populations and Koreans. We comprehensively reviewed the literature and conducted a cross-sectional study to analyze genomic databases, including the Genome Aggregation Database (gnomAD), Korean Variant Archive (KOVA), and Tohoku Medical Megabank Organization (ToMMo), to identify pathogenic SLC25A13 variants in East Asian populations. A founder 3-kilobase (kb) insertion in intron 16 of SLC25A13 was investigated using whole-genome sequencing data from 681 Koreans with the Linux grep command. Twenty-three pathogenic SLC25A13 variants were identified, with c.852_855del being the most common. Analysis of data from 17,501 East Asian individuals in the gnomAD and ToMMo databases revealed a carrier frequency of 1 in 62 people. Analysis of data from 7,214 individuals in the gnomAD and KOVA databases revealed a carrier frequency of 1 in 86, corresponding to an estimated disease prevalence of 1 in 29,502. c.1177+1G>A was identified as the most prevalent pathogenic variant in Koreans. The 3 kb insertion in intron 16 was detected in three out of 681 individuals, indicating a carrier frequency of 1 in 228. The high carrier frequency of citrin deficiency in East Asians highlights the need for enhanced genetic screening and counseling, particularly in Korea, providing a valuable reference for future studies on genetic diversity and pathogenic variants in this population.


  • Open Access

    Pancreatic Cancer Detection and Differentiation from Chronic Pancreatitis: Potential Biomarkers Identified through a High-Throughput Multiplex Proteomic Assay and Machine Learning-Based Analysis

    by Young-Gon Kim, Sang-Mi Kim, Soo-Youn Lee

    Young-gon Kim, M.D., Ph.D., Sang-Mi Kim, M.D., Ph.D., and Soo-Youn Lee, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0492


  • Open Access

    Evaluation of the Commutability of Thyroid-Stimulating Hormone Measurements for Proficiency Testing

    by Jong Hyeon Lee, Sang-Mi Kim, Jong Do Seo, Yeo-Min Yun, Hyung-Doo Park

    Jong Hyeon Lee, Sang-Mi Kim, Jong Do Seo, Yeo-Min Yun, and Hyung-Doo Park. Lab Med Qual Assur 2024;46:200-7. https://doi.org/10.15263/jlmqa.2024.46.4.200


  • Open Access

    Establishment of Preanalytical Quality Indicators and Current Status of Preanalytical Phase Laboratory Performance Monitoring in the Clinical Laboratories in Korea

    by Sang-Mi Kim, Kyunghoon Lee, Sollip Kim, Yong-Wha Lee, Sail Chun, Hyung-Doo Park

    Sang-Mi Kim, Kyunghoon Lee, Sollip Kim, Yong-Wha Lee, Sail Chun, and Hyung-Doo Park. Lab Med Qual Assur 2024;46:145-55. https://doi.org/10.15263/jlmqa.2024.46.3.145

  • Open Access

    Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma

    by Hyun-Woo Lee, Sang-Mi Kim, Hyung-Doo Park

    Objectives: This study evaluates the HYDRASHIFT assay’s effectiveness in mitigating daratumumab interference on serum protein tests during multiple myeloma (MM) treatment, aiming to ensure an accurate assessment of treatment response. Methods: We analyzed 113 serum samples from 68 MM patients undergoing daratumumab treatment, employing both standard IF and the HYDRASHIFT assay. The assay’s precision was determined through intra-day and inter-day variability assessments, while its specificity was verified using serum samples devoid of daratumumab. Comparative analysis of IF results, before and after the application of the HYDRASHIFT assay, facilitated the categorization of treatment responses in alignment with the International Myeloma Working Group’s response criteria. Results: The precision underscored the assay’s consistent repeatability and reproducibility, successfully eliminating interference of daratumumab-induced Gκ bands. Specificity assessments demonstrated the assay’s capability to distinguish daratumumab from both isatuximab and naturally occurring M-proteins. Of the analyzed cases, 91 exhibited successful migration of daratumumab-induced Gκ bands, thereby enhancing the accuracy of treatment response classification. The remaining 22 cases did not show a visible migration complex, likely due to the low concentration of daratumumab in the serum. These findings underscore the assay’s critical role in distinguishing daratumumab from endogenous M-protein, particularly in samples with a single Gκ band on standard IF, where daratumumab and endogenous M-protein had co-migrated. Conclusions: The HYDRASHIFT assay demonstrates high precision, specificity, and utility in the accurate monitoring of treatment responses in MM patients receiving daratumumab. This assay represents a significant advancement in overcoming the diagnostic challenges posed by daratumumab interference.


  • Clinical feature, GALC variant spectrum, and genotype–phenotype correlation in Korean Krabbe disease patients: Multicenter experience over 13 years

    by Narae Hwang, Sang‐Mi Kim, Changhee Ha, Jeehun Lee, Byung‐Ok Choi, Won Jae Sung, Seung Hyun Kim, Young Mi Kim, Yong‐Wha Lee, Jieun Kim, et al.

    Krabbe disease (KD) is an autosomal recessive neurodegenerative disorder caused by deficiency of the galactocerebrosidase (GALC) due to variants in the GALC gene. Here, we provide the first and the largest comprehensive analysis of clinical and genetic characteristics, and genotype-phenotype correlations of KD in Korean in comparison with other ethnic groups. From June 2010 to June 2023, 10 patients were diagnosed with KD through sequencing of GALC. Clinical features, and results of GALC sequencing, biochemical test, neuroimaging, and neurophysiologic test were obtained from medical records. An additional nine previously reported Korean KD patients were included for review. In Korean KD patients, the median age of onset was 2 years (3 months-34 years) and the most common phenotype was adult-onset (33%, 6/18) KD, followed by infantile KD (28%, 5/18). The most frequent variants were c.683_694delinsCTC (23%) and c.1901T>C (23%), while the 30-kb deletion was absent. Having two heterozygous pathogenic missense variants was associated with later-onset phenotype. Clinical features were similar to those of other ethnic groups. In Korean KD patients, the most common phenotype was the adult-onset type and the GALC variant spectrum was different from that of the Caucasian population. This study would further our understanding of KD.


  • Open Access

    Supplementary Figures from Sildenafil Suppresses Inflammation-Driven Colorectal Cancer in Mice

    by Bianca N. Islam, Sarah K. Sharman, Yali Hou, Allison E. Bridges, Nagendra Singh, Sangmi Kim, Ravindra Kolhe, Jimena Trillo-Tinoco, Paulo C. Rodriguez, Franklin G. Berger, et al.